Acute and Subacute Oral Exposure to Inorganic Arsenic Significantly Impacted the Pathology of a Mouse Model With Th2‐ and Th17‐, But Not Th1‐Dependent Allergy Development
Journal of Applied Toxicology,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 13, 2025
ABSTRACT
Increased
blood
levels
of
inorganic
arsenic
compounds
(iAs)
are
associated
with
the
onset
allergic
diseases.
This
study
investigated
direct
relationship
between
oral
exposure
to
iAs
and
several
A
mouse
model
type
1,
2,
17
helper
T
cell
(Th1,
Th2,
Th17)
dependent
allergies
was
generated
in
female
BALB/c
mice
by
topical
treatment
2,4‐dinitrochlorobenzene,
toluene‐2,4‐diisocyanate,
imiquimod.
Several
concentrations
(0,
0.3,
3,
10
mg/kg)
were
administered
orally
for
3
or
4
days
during
each
allergen
challenge.
Itch
behavior
changes
skin
thickness
monitored,
animals
euthanized,
inflammatory
responses
auricular
lymph
nodes
analyzed.
The
influence
subacute
(0.3
24–52
days)
on
development
chronic
Th2
allergy
examined
using
models
TDI‐induced
atopic
dermatitis
Dermatophagoides
farinae
‐induced
asthma.
Acute
significantly
exacerbated
Th2‐
Th17‐dependent
allergies,
whereas
Th1‐dependent
reactions
not
influenced.
corroborated
low
a
allergy.
Symptoms
immune
increased
following
exposure.
Our
findings
imply
that
affects
pathology
development,
but
Язык: Английский
Sub-acute oral exposure to lowest observed adverse effect level of nivalenol exacerbates atopic dermatitis in mice via direct activation of mitogen-activated protein kinase signal in antigen-presenting cells
Archives of Toxicology,
Год журнала:
2024,
Номер
98(7), С. 2173 - 2183
Опубликована: Апрель 14, 2024
Язык: Английский
Oral Exposure to Low Concentration of Fumonisin B2, but Not Fumonisin B1, Significantly Exacerbates the Pathophysiology of Imiquimod-Induced Psoriasis in Mice
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(14), С. 7852 - 7852
Опубликована: Июль 18, 2024
This
study
aimed
to
determine
whether
oral
fumonisin
exposure
contributes
the
development
of
psoriasis.
Oral
administration
B1
(FB1,
0.1
mg/kg)
or
B2
(FB2,
was
conducted
for
10
days,
in
addition
induction
psoriatic
symptoms
through
topical
application
5%
imiquimod
cream
from
day
6
(5
days)
female
BALB/c
mice.
The
results
demonstrated
that
FB2
significantly
exacerbated
symptoms,
including
skin
thickness,
itching
behavior,
transepidermal
water
loss,
immune
cell
infiltration
dermis,
and
proinflammatory
cytokine
production.
However,
no
changes
were
observed
following
FB1.
Our
confirm
adversely
affects
pathogenesis
psoriasis
by
increasing
thickness
impairing
barrier
function.
Язык: Английский